60 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Feasibility (Recruitment Rates)Primary· Four weeks
Percentage of patients who consented to the study ultimately completed the study intervention and post-intervention assessment
Group
Value
95% CI
Experimental: Experimental Arm: Single
11
UsefulnessPrimary· Four weeks
Usefulness was assessed using the Preparation for Decision Making Scale (mean score range from 1 to 5, and higher scores indicate greater usefulness)
Group
Value
95% CI
Experimental: Experimental Arm: Single
3.8
± 0.7
Pre-post Changes in the Following Outcomes:Perceived Efficacy in Patient-Physician Interactions (PEPPI)Secondary· Four weeks
A valid and reliable assessment of perceived self-efficacy of older patients interacting with physicians; score on 5-item scale, ranging 5-25; higher score corresponds to greater perceived efficacy. Pre-post changes from baseline to four weeks.
Group
Value
95% CI
Experimental: Experimental Arm: Single
1.5
± 3.0
Pre-post Changes in the Following Outcomes: General Anxiety Disorder-7Secondary· Four weeks
A 7-item screening tool for anxiety; ranging 7-21; higher score corresponds to greater anxiety symptoms. Pre-post changes from baseline to four weeks.
Group
Value
95% CI
Experimental: Experimental Arm: Single
-1.6
± 5.4
Pre-post Changes in the Following Outcomes: Geriatric Depression Scale-15Secondary· Four Weeks
A 15-item valid and reliable screening tool for depression in older adults. This will be used for patients; ranging 0-15; higher score corresponds to greater depressive symptoms. Pre-post changes from baseline to four weeks.
Group
Value
95% CI
Experimental: Experimental Arm: Single
0.2
± 2.1
Sponsor's own description
This is a pilot study to evaluate the usability and feasibility of a patient-centered communication tool (University of Rochester-Geriatric Oncology Assessment for acute myeloid Leukemia or UR-GOAL) among 15 older patients with AML, their caregivers, and oncologists.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
· Phase 1
· recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I
· Phase 2
· recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML
· Phase 1
· recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
· Phase 1
· recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
· Phase 1
· recruiting
Other University of Rochester trials
Trials by the same sponsor.
NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1
· Phase 1
· not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi
· Phase 2
· not yet recruiting
NCT05744869 — SBAT for Health Equity
· NA
· not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
· Phase 2
· not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04625413.